A Phase I/II Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients
Phase of Trial: Phase I/II
Latest Information Update: 09 Jul 2019
Price : $35 *
At a glance
- Drugs Decitabine (Primary) ; Ribavirin; Sirolimus
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 03 Jul 2019 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 03 Jul 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Jun 2020.
- 31 Aug 2018 Biomarkers information updated